Alvine Pharmaceuticals, Inc. (extinct)

Alvine Pharmaceuticals, Inc. (extinct)

Alvine Pharmaceuticals, Inc. (extinct)

Overview
Date Founded

2005

Headquarters

75 SHOREWAY ROAD SUITE B SAN CARLOS CA 94070

Type of Company

Private

Employees (Worldwide)

11 - 50

Industries

Hospitals & Patient Services
Biotechnology
Pharmaceuticals

Company Description

Alvine Pharmaceuticals, Inc. develops and commercializes therapeutics for inflammatory diseases. It offers ALV003, tTG Inihibitors and HLA-DQ2 Blockers. The company was founded by Blair Stewart and Kevin R. Kaster in 2005 and is headquartered in San Carlos, CA.

Contact Data
Trying to get in touch with decision makers at Alvine Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Paths to Alvine Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Alvine Pharmaceuticals, Inc.
Recent Transactions
Details Hidden

ImmunogenX LLC, Immunogenics LLC purchase Alvine Pharmaceuticals, Inc. from Prospect Venture Partners, Panorama Capital LLC, Abbott Ventures, Inc., Proterra Investment Partners LP, Flagship Pioneering, Sofinnova Ventures, Inc., InterWest Partners, LLC, AbbVie Biotech Ventures, Inc.

Details Hidden

Alvine Pharmaceuticals, Inc. raised money in a private placement transaction

Details Hidden

Alvine Pharmaceuticals, Inc. raised money in a private placement transaction

Investors
Details Hidden

Black River Asset Management LLC, combined with its subsidiaries around the world (together "Black River") is a diversified investment organization offering focused investment strategies. Our firm is regarded for its strong team, culture, broad perspectives, and core competencies. This includes deeply entrenched capabilities in fixed income and equity markets; a unique understanding of the emerging markets; and an embedded knowledge of commodity-related trading and investing. Black River has been registered as an Investment Adviser with the Securities and Exchange Commission since the firm's inception. We leverage our firm's key attributes to inform our investment process, drive performance and deliver meaningful client service as an entrusted partner. The pillars of our approach reflect: Ownership: Cargill was founded in 1865 and remains a privately owned company employing 142,000 people in 65 countries. Our parent company affords Black River a substantial global presence and demonstrates its commitment to our firm by investing alongside our employees and clients. Integrity: Throughout its life, Cargill has maintained a deeply held commitment to the highest ethical standards. Black River operates with the same principles. Our commitment to ethical conduct infuses our culture, our relationships with investors and counterparties, and our dedication to building the business for the long term. Experienced Leadership: Our senior leadership team has worked together for 18 years, combining investment skills and experience across all asset classes. The team has weathered a variety of volatile market cycles. We provide a steady and experienced hand, both in pursuing significant market opportunities and managing challenging market conditions. Investment Capabilities: Our investment team is a seasoned group of more than 80 portfolio managers and research analysts. Operating from a network of 13 offices in 11 countries, our keen understanding of global financial markets helps us identify opportunities and exploit inconsistencies. Because of their in-country presence, our local market experts provide exceptional insight into emerging economies, allowing us to take advantage of new opportunities and trends. Transparency: We are committed to providing the transparency and information that institutional investors require for managing their portfolios. Our robust infrastructure includes more than 70 professionals providing risk management, law, tax, compliance, finance, investor relations and other support. Investor Solutions: We offer investors highly focused trading and investing solutions that leverage the full strengths of our firm. Through an emphasis on collaboration and innovation, we develop products and services that capitalize on market opportunities and address investor needs. This includes the flexibility to create a tailored experience for our clients.

Details Hidden

Panorama Capital focuses on investments in the life sciences and technology industries. The firm looks for companies with exceptional management teams and the potential to become market leaders in their industries. They invest in companies from the seed stage to later-stage companies with more established businesses. Within the life sciences sector, Panorama Capital focuses on companies that are developing therapeutics that address significant unmet medical needs and that have a well-defined mechanism of action and clinical/regulatory strategy. The firm's technology investments focus on companies with business models that are operating in sectors in which the firm has significant domain expertise. Panorama Capital's investments typically range from $6 million to $18 million over the life of a company

Details Hidden

Flagship Pioneering seeks investment opportunities in companies located globally. The firm focuses on companies operating in the fields of therapeutics, life science tools & diagnostics, and bioenergy or cleantech. It provides financing for seed, early, and later-stage capital requirements. It acts as a lead investor. It also makes co-investments.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Alvine Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Alvine Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Alvine Pharmaceuticals, Inc..